NewsRoom Articles - Page 172 of 223

FridayMay 07, 2021 12:15 pm

Researchers Propose That Existing Drugs May Help Treat COVID-19

It can take anywhere between a few years to several decades for researchers to develop drugs for various illnesses. However, time is not a luxury that has been afforded to researchers working on therapies to treat patients suffering from the coronavirus. This is why researchers from Northeastern University, in collaboration with Harvard University researchers, devised another way to find treatments for this fatal disease by analyzing treatments already in existence. The group of researchers have published their findings in the “Proceedings of the National Academy of Sciences.” The researchers analyzed all treatments currently available to patients for the treatment of…

ThursdayMay 06, 2021 11:02 am

Researchers Find Possible Cause of Silent Hypoxia in Coronavirus Patients

Researchers still don’t know a lot about the novel coronavirus and how it attacks various organs in the body. However, among the biggest mysteries of this disease is how it causes oxygen levels in an individual’s body to become abnormally low. This condition, usually referred to as silent hypoxia, irreversibly damages an individual’s vital organs if it remains undetected for an extended period of time. With the help of computer models, biomedical engineers from Boston University have begun to get to the bottom of this mystery. Their study, which was reported in the “Nature Communications” journal, was conducted in collaboration…

ThursdayMay 06, 2021 10:45 am

Brain Scientific Inc. (BRSF) Eyes Plans for 2021 and Beyond

Commercial application of NeuroEEG and NeuroCap growing across ICUs, acute inpatient care and other emergency care in U.S. BRSF plans to launch devices in Canada Company expands footprint, plans patent applications in Latin America, Europe Brain Scientific (OTCQB: BRSF), a neurology-focused medical device and software company, has unveiled the outlook for 2021. Brain Scientific continues to make strides within neurology by revolutionizing the brain diagnostic market with its groundbreaking technology. The company recently announced that its R&D efforts surged in 2020 with an investment of $275,926, which marks a 266% increase over 2019’s total of $103,616 (https://ibn.fm/Uiqs7). Despite a challenging…

WednesdayMay 05, 2021 2:50 pm

Researchers Find Young People Can Get Re-infected by the Coronavirus

In most cases, when an individual gets infected with a disease, their body creates antibodies to protect them from the infection were it to occur again. However, researchers have discovered that while SARS-CoV-2 antibodies are protective, they don’t protect young individuals against reinfection. This can be observed in the findings of a longitudinal study that was conducted by scientists from the Naval Medical Research Center and the Icahn School of Medicine at Mount Sinai. The study’s results were reported in “The Lancet Respiratory Medicine Journal.” The senior author of the study, Stuart Sealfon, stated that the findings indicate that SARS-CoV-2…

WednesdayMay 05, 2021 12:03 pm

Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Signs Drug-Development Agreement, One Step Closer to Effective Psychiatric Disorder Treatment

Agreement calls for Cybin, Catalent to work together to develop novel therapy for treatment-resistant psychiatric disorders Cybin looking to identify fast-acting, shorter-duration formulations of CYB003 Delivering CYB003 through Catalent ODT could provide significant benefits Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, has inked a drug-development agreement with Catalent Inc. (NYSE: CTLT), a leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products (https://ibn.fm/nQdpg). The agreement, which is scheduled to start this month, calls for the two companies to work together to potentially…

TuesdayMay 04, 2021 2:24 pm

XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Inks Distribution Agreement for Rapid COVID-19 Test Kits; Expands Commercial Leadership Team in Anticipation of Strong, Sustainable Sales

XPhyto Therapeutics Corp. recently announced it has entered into a distribution, storage and logistics agreement with a German distributor with an established network throughout Germany Germany holds promise due to regulations requiring mandatory weekly testing for its citizens; this has the possibility of ramping up sales Anticipating the increase in sales and distribution, XPhyto expanded its commercial leadership team by bringing on board Mr. Wolfgang Probst and Mr. Manfred Buchberger Mr. Probst will be the company’s Chief Operations Officer (“COO”), while Mr. Buchberger will be the Head of Corporate Development at wholly owned subsidiary XP Diagnostics GmbH The approvals XPhyto…

TuesdayMay 04, 2021 1:48 pm

Computer Analysis May Help Create Personalized Healthy Diets

A mathematical model developed by scientists from Sweden’s Chalmers University of Technology has been designed to help researchers create tailored diets and new probiotics to prevent illnesses. The lead author of the study, Prof. Jens Nielsen, explained that intestinal bacteria played a crucial role in the development of illnesses and the quality of an individual’s health and noted that the mathematical model would be very helpful in these areas. The study was reported in the “PNAS” journal. The new study highlights the performance of the mathematical model in making predictions associated with a couple of prior clinical studies: one that…

TuesdayMay 04, 2021 11:41 am

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Leading Charge in Developing Psychedelic Medicines for Treating Rare Eating Disorders

Pharmaceutical developer Tryp Therapeutics is targeting orphan disorders with novel medicinal solutions The company’s initial candidates seeking regulatory approval are a psilocybin compound for treating fibromyalgia, eating disorders and chronic pain conditions, as well as a tumor-inhibiting drug for treating soft tissue sarcomas Tryp has partnered with the University of Florida to conduct a Phase 2a clinical trial for eating disorders using Tryp's psilocybin product Following a year in which a global pandemic led to heightened concerns about individuals’ mental well-being while navigating the health emergency’s effects on society (https://ibn.fm/YGqDb), proponents of psychedelic medicine development programs gained stronger allies in…

TuesdayMay 04, 2021 10:58 am

RYAH Group About to Start Trading on Canadian Securities Exchange

RYAH Group to start trading on Canadian Securities Exchange following a transaction involving a triangular merger RYAH Group is digital health care analytics and technology company developing innovative solutions for the plant-based medical industry RYAH is poised for growth as the world transitions to remote health at an accelerated pace due to the pandemic RYAH Group (formerly known as Prime Blockchain Inc.) will start trading on the Canadian Securities Exchange under the ticker symbol "RYAH" today (https://ibn.fm/Z6gZj). The New York-based digital health care analytics and technology company is focused on the development and commercialization of innovative technology, including software and…

MondayMay 03, 2021 2:51 pm

DGE’s 4th Virtual Clinical Trials Conference

Monday, May 17, 2021 On Monday, May 17th, 2021, pharma companies, medical vendors, and clinicians are invited to attend the 4th Virtual Clinical Trials conference – the industry’s leading, longest-lasting conference on virtual clinical trials. The event is hosted by Dynamic Global Events (“DGE”), a Life Science Leader in organizing B2B Events. The global event company caters to the dynamic informational and networking needs of the Pharmaceutical, Biotechnology, Healthcare, Medical Devices, and allied industries. On May 17-18th The 4th Virtual Clinical Trials will increase your ability to execute your decentralized trial, reduce site visits, accelerate timelines and gather data faster. Hear from top industry…